Intercept Pharmaceuticals, Inc. (ICPT) CFO Sells $20,825.82 in Stock
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CFO Sandip Kapadia sold 354 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.83, for a total value of $20,825.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded down 3.39% on Friday, reaching $65.49. The company’s stock had a trading volume of 1,049,123 shares. The stock’s market capitalization is $1.64 billion. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $142.10. The stock has a 50-day moving average of $86.63 and a 200 day moving average of $108.69.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period in the prior year, the company earned ($3.14) EPS. On average, analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.99) EPS for the current year.
A number of brokerages have issued reports on ICPT. JMP Securities lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 4th. Wedbush reissued an “outperform” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. Royal Bank Of Canada raised their price target on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 26th. Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Finally, Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $153.76.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WFG Advisors LP boosted its position in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE bought a new position in Intercept Pharmaceuticals in the 1st quarter valued at $130,000. IFP Advisors Inc boosted its position in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Intercept Pharmaceuticals in the 1st quarter valued at $170,000. Institutional investors and hedge funds own 82.19% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.